Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQA2225/AP025 in Adults With Nonalcoholic Steatohepatitis (NASH)
NCT06569524Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TQA2225 in Nonalcoholic steatohepatitis (NASH) (2 cohorts), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoint: Change in NASH CRN Score on Liver Biopsy at 48 weeks. Started Sep 2023; status: recruiting.
02
Drugs
TQA2225
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06569524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569524.